# The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam

> **NCT01221727** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 30 (actual)

## Conditions studied

- Postmenopausal Osteoporosis

## Interventions

- **DRUG:** Denosumab
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT01221727
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01221727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01221727, "The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01221727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*